



Supplementary Figure 1.



Supplementary Figure 2.




C


Definitions of HPD	Using parameters	Cases of patient (n=121)	Cases of immunotherapy (n=136)
HPDc	RECIST progression, TGR-exp/TGR-ref >2	4 (3.3)	5 (2.9)
mHPDc	HPDc + new lesions	14 (11.6)	18 (13.2)
HPDs	TGK-exp/TGK-ref >2	11 (9.1)	14 (10.3)
mHPDs	HPDs + new lesions	17 (14.0)	22 (16.2)
HPDf	RECIST progression, TGR-exp/TGR-ref >50%	0 (0.0)	0 (0.0)
mHPDf	HPDf + new lesions	12 (9.9)	16 (11.8)

Supplementary Figure 3.

A




B




Supplementary Figure 4.

A




HPDc


B



mHPDc




HPDs




mHPDs

Supplementary Figure 5.


A



B



C



D

